The acquisition of ocular gene therapy company, Gyroscope, adds GT005 to the Novartis portfolio – a one-time gene therapy for geographic atrophy, a leading cause of blindness
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.